A detailed history of New England Research & Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, New England Research & Management, Inc. holds 13,092 shares of ABBV stock, worth $2.3 Million. This represents 1.21% of its overall portfolio holdings.

Number of Shares
13,092
Previous 11,476 14.08%
Holding current value
$2.3 Million
Previous $1.97 Million 31.35%
% of portfolio
1.21%
Previous 0.95%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$163.84 - $199.33 $264,765 - $322,117
1,616 Added 14.08%
13,092 $2.59 Million
Q2 2024

Jul 09, 2024

BUY
$154.79 - $180.76 $991,894 - $1.16 Million
6,408 Added 126.44%
11,476 $1.97 Million
Q1 2024

Apr 16, 2024

BUY
$159.82 - $182.1 $6,552 - $7,466
41 Added 0.82%
5,068 $923,000
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $78,844 - $88,797
-573 Reduced 10.23%
5,027 $779,000
Q3 2023

Oct 10, 2023

SELL
$133.59 - $154.65 $44,485 - $51,498
-333 Reduced 5.61%
5,600 $835,000
Q2 2023

Jul 05, 2023

SELL
$132.51 - $164.9 $2,915 - $3,627
-22 Reduced 0.37%
5,933 $799,000
Q1 2023

Apr 06, 2023

SELL
$144.61 - $166.54 $14,461 - $16,654
-100 Reduced 1.65%
5,955 $949,000
Q4 2022

Jan 09, 2023

SELL
$138.31 - $165.87 $425,303 - $510,050
-3,075 Reduced 33.68%
6,055 $979,000
Q3 2022

Oct 06, 2022

BUY
$134.21 - $153.93 $416,051 - $477,183
3,100 Added 51.41%
9,130 $1.23 Million
Q1 2022

Apr 20, 2022

SELL
$131.98 - $163.75 $1.27 Million - $1.58 Million
-9,628 Reduced 61.49%
6,030 $978,000
Q3 2021

Oct 08, 2021

SELL
$106.4 - $120.78 $7,980 - $9,058
-75 Reduced 0.48%
15,658 $1.69 Million
Q2 2021

Jul 15, 2021

SELL
$105.21 - $117.21 $5,260 - $5,860
-50 Reduced 0.32%
15,733 $1.77 Million
Q1 2021

Apr 16, 2021

BUY
$102.3 - $112.62 $6,444 - $7,095
63 Added 0.4%
15,783 $1.71 Million
Q4 2020

Jan 07, 2021

BUY
$80.49 - $108.67 $88,539 - $119,537
1,100 Added 7.52%
15,720 $1.68 Million
Q3 2020

Oct 08, 2020

SELL
$85.91 - $100.83 $7,302 - $8,570
-85 Reduced 0.58%
14,620 $1.28 Million
Q2 2020

Jul 15, 2020

BUY
$73.37 - $98.18 $348,507 - $466,355
4,750 Added 47.71%
14,705 $1.44 Million
Q1 2020

Jun 15, 2020

SELL
$64.5 - $97.79 $27,412 - $41,560
-425 Reduced 4.09%
9,955 $758,000
Q4 2019

Jan 14, 2020

SELL
$72.13 - $90.25 $104,588 - $130,862
-1,450 Reduced 12.26%
10,380 $919,000
Q3 2019

Nov 04, 2019

BUY
$62.98 - $75.72 $299,155 - $359,670
4,750 Added 67.09%
11,830 $896,000
Q2 2019

Jul 09, 2019

SELL
$65.7 - $83.98 $70,890 - $90,614
-1,079 Reduced 13.22%
7,080 $515,000
Q1 2019

Apr 03, 2019

BUY
$77.14 - $90.79 $23,142 - $27,237
300 Added 3.82%
8,159 $658,000
Q4 2018

Jan 11, 2019

SELL
$77.85 - $96.01 $441,720 - $544,760
-5,674 Reduced 41.93%
7,859 $725,000
Q3 2018

Oct 03, 2018

SELL
$88.91 - $98.84 $235,611 - $261,926
-2,650 Reduced 16.38%
13,533 $1.28 Million
Q2 2018

Jul 05, 2018

BUY
$89.78 - $106.23 $166,093 - $196,525
1,850 Added 12.91%
16,183 $1.5 Million
Q1 2018

Apr 17, 2018

BUY
$92.01 - $123.21 $901,698 - $1.21 Million
9,800 Added 216.19%
14,333 $1.36 Million
Q4 2017

Jan 09, 2018

SELL
$89.56 - $98.21 $427,649 - $468,952
-4,775 Reduced 51.3%
4,533 $438,000
Q3 2017

Oct 25, 2017

BUY
$69.85 - $89.22 $650,163 - $830,459
9,308
9,308 $827,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track New England Research & Management, Inc. Portfolio

Follow New England Research & Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New England Research & Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on New England Research & Management, Inc. with notifications on news.